MedPath

EMORY UNIVERSITY

EMORY UNIVERSITY logo
🇺🇸United States
Ownership
Private
Established
1836-12-10
Employees
10K
Market Cap
-
Website
http://www.emory.edu

Clinical Trials

1.3k

Active:62
Completed:798

Trial Phases

6 Phases

Early Phase 1:25
Phase 1:142
Phase 2:204
+3 more phases

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (1125 trials with phase data)• Click on a phase to view related trials

Not Applicable
566 (50.3%)
Phase 2
204 (18.1%)
Phase 4
146 (13.0%)
Phase 1
142 (12.6%)
Phase 3
42 (3.7%)
Early Phase 1
25 (2.2%)

Time-of-Day Specified Ipilimumab and Nivolumab for the Treatment of Stage IV Unresectable Melanoma, The TIME Trial

Not Applicable
Not yet recruiting
Conditions
Advanced Acral Melanoma
Advanced Cutaneous Melanoma
Advanced Mucosal Melanoma
Clinical Stage IV Cutaneous Melanoma AJCC v8
Metastatic Acral Melanoma
Metastatic Cutaneous Melanoma
Metastatic Mucosal Melanoma
Unresectable Acral Melanoma
Unresectable Cutaneous Melanoma
Unresectable Mucosal Melanoma
Interventions
Procedure: Biopsy Procedure
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Procedure: Magnetic Resonance Imaging
Other: Medical Device Usage and Evaluation
Other: Questionnaire Administration
First Posted Date
2025-09-04
Last Posted Date
2025-09-04
Lead Sponsor
Emory University
Target Recruit Count
99
Registration Number
NCT07155317
Locations
🇺🇸

Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States

🇺🇸

Emory Saint Joseph's Hospital, Atlanta, Georgia, United States

Cranial Electrotherapy Stimulation and Brain Imaging for Gulf War Syndrome

Not Applicable
Not yet recruiting
Conditions
Gulf War Syndrome
First Posted Date
2025-09-03
Last Posted Date
2025-09-03
Lead Sponsor
Emory University
Target Recruit Count
130
Registration Number
NCT07151248
Locations
🇺🇸

Emory Clinic, Atlanta, Georgia, United States

Combination External Radiation and PRRT for Large GI Neuroendocrine Tumors.

Not Applicable
Not yet recruiting
Conditions
Digestive System Neuroendocrine Tumor
Unresectable Digestive System Neuroendocrine Neoplasm
Unresectable Digestive System Neuroendocrine Tumor G1
Unresectable Digestive System Neuroendocrine Tumor G2
Interventions
Radiation: Stereotactic Body Radiation Therapy
Procedure: Computed Tomography
Procedure: Magnetic Resonance Imaging
Radiation: Gallium Ga 68-DOTATATE
Procedure: Positron Emission Tomography
Other: Questionnaire Administration
First Posted Date
2025-09-02
Last Posted Date
2025-09-02
Lead Sponsor
Emory University
Target Recruit Count
15
Registration Number
NCT07150546
Locations
🇺🇸

Emory University Hospital Midtown, Atlanta, Georgia, United States

🇺🇸

Emory University Hospital, Atlanta, Georgia, United States

Evaluating Georgia Part C Implementation Outcomes

Not Applicable
Not yet recruiting
Conditions
Communication Disorder, Childhood
Autism
First Posted Date
2025-08-29
Last Posted Date
2025-08-29
Lead Sponsor
Emory University
Target Recruit Count
80
Registration Number
NCT07148258
Locations
🇺🇸

Marcus Autism Center, Atlanta, Georgia, United States

CARE-D-FOOT-Nav Pilot

Not Applicable
Recruiting
Conditions
Diabetic Foot Ulcer (DFU)
First Posted Date
2025-08-27
Last Posted Date
2025-08-27
Lead Sponsor
Emory University
Target Recruit Count
25
Registration Number
NCT07143175
Locations
🇺🇸

Grady Memorial Hospital, Atlanta, Georgia, United States

🇺🇸

Emory University Hospital Midtown, Atlanta, Georgia, United States

🇺🇸

Emory University Hospital (EUH), Atlanta, Georgia, United States

and more 1 locations
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 268
  • Next

News

Virax Biolabs Partners with Emory University for Long COVID Diagnostic Study Using T Cell Technology

Virax Biolabs has signed a Research Services Agreement with Emory University's ADJUST Center to conduct clinical studies of ViraxImmune™ technology for diagnosing long COVID and other post-viral syndromes.

Aligos Therapeutics Initiates Phase 2 Trial of ALG-000184 for Chronic Hepatitis B Treatment

Aligos Therapeutics has begun dosing patients in the Phase 2 B-SUPREME study of ALG-000184, an investigational oral therapy for chronic hepatitis B virus infection.

Psilocybin Shows Anti-Aging Properties in Preclinical Study, Extending Cellular Lifespan by 50%

Emory University researchers demonstrated that psilocin, the active metabolite of psilocybin, extended human skin and lung cell lifespans by more than 50% in laboratory studies.

CDC Sponsors First Clinical Trial of Needle-Free Rotavirus Vaccine Using Dissolvable Microarray Patch Technology

Emory University and Micron Biomedical have launched the first CDC-sponsored clinical trial of a rotavirus vaccine delivered via dissolvable microarray patch technology, marking a significant milestone in needle-free vaccine administration.

Ryght AI Secures $3M Seed Funding and Expands Academic Partnerships to Accelerate Clinical Trial Site Selection

Ryght AI raised $3 million in seed funding led by Foothill Ventures to advance its AI-powered clinical trial platform that creates digital twins of over 100,000 research sites worldwide.

FDA Approves Hundreds of Drugs Without Adequate Evidence of Effectiveness, Investigation Reveals

A two-year investigation found that 73% of the 429 drugs approved by the FDA from 2013-2022 failed to meet the agency's four foundational standards for proving effectiveness.

Long-Term Study Confirms Hydroxyurea's Safety and Efficacy in Pediatric Sickle Cell Disease

Children with sickle cell disease taking hydroxyurea experienced fewer emergency room visits and shorter hospital stays compared to those not on the therapy, according to a study of 2,147 pediatric patients.

Vaccinex's Pepinemab Shows Promise in Turning "Cold" Tumors "Hot" Through Enhanced Immune Response

Vaccinex will present new clinical data at ASCO 2025 showing that neoadjuvant treatment with pepinemab induces mature tertiary lymphoid structures that correlate with improved pathologic response in head and neck cancer patients.

Loneliness Epidemic Shifts: Middle-Aged Americans More Isolated Than Seniors, New Research Reveals

One-third of Americans aged 50-80 report feeling lonely, with rates returning to pre-pandemic levels after peaking at 42% during COVID-19, according to University of Michigan research.

Expanded GLP-1 Drug Access Could Save 42,000 Lives and Billions in Healthcare Costs Annually

Expanding access to GLP-1 weight-loss medications like Ozempic and Zepbound could prevent more than 42,000 deaths annually in the United States, according to a recent Yale study published in PNAS.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.